UBS Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$614K Buy
+25,100
New +$699K ﹤0.01% 6053
2021
Q2
– Sell
-49,600
Closed -$3.97M – 9382
2021
Q1
$3.97M Buy
+49,600
New +$4.72M ﹤0.01% 2861

Other funds holding BEAM

UBS Group's BEAM Position: Q3 2026 in Review

UBS Group increased its Beam Therapeutics (BEAM) stake by 6.2% in Q3 2026, buying an estimated $994K and bringing the position to 610,513 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

UBS Group first reported a position in BEAM in Q1 2020 and has held it in 27 quarters since. The position peaked at $45.1M in Q4 2024. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • UBS Group held 610,513 shares of Beam Therapeutics worth $14.9M as of Q3 2026.
  • UBS Group bought 35,699 Beam Therapeutics shares in Q3 2026, an estimated $994K.
  • Beam Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2979 holding.
  • UBS Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 27 quarters since.
  • UBS Group's Beam Therapeutics position peaked at $45.1M in Q4 2024.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.